Regeneron (REGN) Reports Positive 84-Week OPTIMA Trial Results for Pasatru in FOP Patients
· gurufocus.com
On October 12, 2026, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the 84-week findings from its Phase 3 OPTIMA trial evaluating Pasatru in adults with
On October 12, 2026, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the 84-week findings from its Phase 3 OPTIMA trial evaluating Pasatru in adults with...